G1 Therapeutics Inc Stock News

Effective Today, New J-code to Streamline Reimbursement Effective Today, New J-code to Streamline Reimbursement

- New G1 Sales Force to Focus on Top Tier Accounts to Accelerate Sales Activities - - New G1 Sales Force to Focus on Top Tier Accounts to Accelerate Sales Activities -

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upc

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerci

G1 Therapeutics is now a commercialization-stage operator having a potential mega-blockbuster (Cosela). Cosela is filling a heightened demand to treat myelosuppression associated with chemotherapy.

GTHX is down considerably from its February highs. Recently approved Cosela is starting out well.

The heavy selling pressure might have exhausted for G1 THERAPEUTICS (GTHX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ana

G1 Therapeutics, Inc. (GTHX) CEO John Bailey on Q2 2021 Results - Earnings Call Transcript

G1 THERAPEUTICS (GTHX) delivered earnings and revenue surprises of 2.08% and 144.77%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., July 19, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the U.S. Food and Drug Administration (F

RESEARCH TRIANGLE PARK, N.C., July 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercis

RESEARCH TRIANGLE PARK, N.C., June 18, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Alicia Secor to its Board

RESEARCH TRIANGLE PARK, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey

G1 Therapeutics Inc (NASDAQ: GTHX) has initiated the PRESERVE 3 Phase 2 study evaluating Cosela (trilaciclib) in patients with untreated, locally advanced, or metastatic urothelial carcinoma (mUC).